Bioperfectus Obtained CE Mark for the SARS-CoV-2 Antigen Rapid Self-test

Company news
2021-12-28

Bioperfectus is pleased to announce that we have obtained CE Mark for our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test). This test is a lateral flow test intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms.

 

 

Our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in German and Austrian markets since May 20th, 2021. With the CE Mark, our test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.

 

 

As the global economy starts to re-open, individuals or communities can follow the easy instruction of our test and detect whether they are infected with SARS-CoV-2 to avoid the further spread of the disease.

 

For further information, please send us an inquiry email: info@bioperfectus.com or  marketing_global@bioperfectus.com.

MOST READ

Your Problem, Our Solution

At Bioperfectus, the excellent experience of our customers is our goal and the key to our job. Last Wednesday, we completed online technical training for our distribution local support in the Asia Pacific region. The webinar covers insightful training on Bioperfectus Nucleic Acid Extraction System, Nucleic Acid Extraction Kit, Real-Time PCR System, and product demonstration on the newly launched SAW-96 Nucleic Acid Extraction Workstation.

2022-08-16

MHRA Registration Approval for BioPerfectus Monkeypox Virus Real Time PCR Kit

Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “BioPerfectus”) is pleased to announce that Monkeypox Virus Real Time PCR Kit has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and is now officially available for Great Britain and Northern Ireland market.

2022-08-11

A Simplified HPV-DNA Workflow for Better Preventing Cervical Cancer

With over 600 thousand new cases and more than half that would lead to death each year, cervical cancer is listed as the fourth most frequent cancer among women worldwide.

2022-08-05